AYTU BIOPHARMA, INC Cash Flow Statement
AYTU|12 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 12 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$2M
FY2025
Free Cash Flow
-$2M
FY2025
Capital Expenditures
$228,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
AYTU BIOPHARMA, INC used $2M in operating cash flow and negative free cash flow of $2M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -71.5% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$13.6M | -$15.8M | -$17.1M | -$108.8M | -$58.3M | -$13.6M | -$10.2M | -$22.5M | -$28.2M | -$7.7M | -$568.2K | -$59.7K |
| Depreciation & Amortization | - | $8.3M | $8.8M | $10.1M | $9.2M | $5.7M | $2.6M | $4.4M | $874.8K | $118.2K | $58.4K | $53.4K |
| Operating Cash Flow | -$1.9M | -$1.4M | -$5.1M | -$28.8M | -$26.0M | -$28.4M | -$15.9M | -$13.8M | -$10.7M | -$6.6M | -$323.5K | -$37.8K |
| Capital Expenditures | $228.0K | $329.0K | - | $0 | $2.3M | $0 | $74.7K | $111.6K | $252.9K | $0 | $26.9K | $26.9K |
| Free Cash Flow | -$2.2M | -$1.7M | - | -$28.8M | -$28.3M | -$28.4M | -$16.0M | -$13.9M | -$10.9M | -$6.6M | -$350.4K | -$64.7K |
| FCF Margin | -3.3% | -2.6% | - | -29.8% | -43.1% | -102.7% | -437.5% | -432.7% | -425.8% | -2534.3% | -6673.5% | -3698.2% |